2014 - Page 3 of 5 - Bay City Capital

Filters

Portfolio News

July 2, 2014

Aciex to be Acquired by Nicox S.A.

Portfolio News

July 1, 2014

Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement

Bay City Capital News

June 19, 2014

Innovative Medicine: The Balance Between Benefits and Costs

By David Beier (Contributor)

Events

June 19, 2014

BIO2014 International Convention

Panel – Son of a Pitch – Do You Have the Talent to Engage Investors
Ashley Dombkowski, PhD
June 23-26, 2014
San Diego, CA

Portfolio News

June 17, 2014

EnteroMedics Announces FDA Advisory Committee Recommendation on VBLOC(R) Vagal Blocking Therapy for the Treatment of Obesity

Portfolio News

June 3, 2014

Omicia and LabCorp Collaborate to Offer Comprehensive Genomic Analysis Services for Next-Generation Clinical Trials

Portfolio News

June 3, 2014

Hyperion Therapeutics Announces Health Canada Accepts RAVICTI(R) New Drug Submission With Priority Review

Portfolio News

June 2, 2014

William Gerber, MD Appointed CEO at SynGen, Inc.

Portfolio News

May 7, 2014

Epizyme Initiates Pediatric MLL-r Proof-of-Concept Study for EPZ-5676

Events

May 5, 2014

Cancer Advance New York

Conference Co-host
Ashley Dombkowski, PhD
May 13-14, 2014
New York, NY

Bay City Capital News

April 30, 2014

Forbes Guest Post by Ashley Dombkowski, PhD

Healthcare's Innovation Imperative: Ten Truths Entrepreneurs Need to Know

Portfolio News

April 28, 2014

Civitas Therapeutics Announces Positive Phase 2b Results for CVT-301, Inhaled Levodopa for the Treatment of Parkinson’s Disease

Portfolio News

April 24, 2014

Hyperion Therapeutics to Broaden Orphan Disease Pipeline With Acquisition of Andromeda Biotech Ltd.

Portfolio News

April 24, 2014

Epizyme Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treatment for Cancers with EZH2 Inhibitors

Portfolio News

April 22, 2014